Mechanisms of immunomodulation by glatiramer acetate

B Gran, LR Tranquill, M Chen, B Bielekova, W Zhou… - Neurology, 2000 - AAN Enterprises
B Gran, LR Tranquill, M Chen, B Bielekova, W Zhou, S Dhib–Jalbut, R Martin
Neurology, 2000AAN Enterprises
Objective: To define the mechanism of action of glatiramer acetate (GA; formerly known as
copolymer-1) as an immunomodulatory treatment for MS. Background: The proposed
mechanisms of action of GA include 1) functional inhibition of myelin-reactive T cells by
human leukocyte antigen (HLA) blocking, 2) T-cell receptor (TCR) antagonism, and 3)
induction of T helper 2 (Th2) immunomodulatory cells. In this report, the authors examined
the effects of GA on the functional activation of human T-cell clones (TCC) specific for myelin …
Objective: To define the mechanism of action of glatiramer acetate (GA; formerly known as copolymer-1) as an immunomodulatory treatment for MS.
Background: The proposed mechanisms of action of GA include 1) functional inhibition of myelin-reactive T cells by human leukocyte antigen (HLA) blocking, 2) T-cell receptor (TCR) antagonism, and 3) induction of T helper 2 (Th2) immunomodulatory cells. In this report, the authors examined the effects of GA on the functional activation of human T-cell clones (TCC) specific for myelin basic protein (MBP) and for foreign antigens. Several questions were addressed: Is the inhibitory effect of GA specific for autoantigens? Is it mediated by blocking the interaction between peptide and HLA molecule? Is GA a partial agonist or TCR antagonist, or does it induce anergy? Does it induce Th2 modulatory T cells?
Methods: The effects of GA on antigen-induced activation of human TCC specific for MBP, influenza virus hemagglutinin, and Borrelia burgdorferi were studied by proliferation and cytokine measurements, TCR downmodulation, and anergy assays. GA-specific TCC were generated in vitro from the peripheral blood of patients and healthy controls by limiting dilution.
Results: GA more strongly inhibited the proliferation of MBP, as compared with foreign antigen-specific TCC; in some MBP-specific TCC, the production of Th1-type cytokines was preferentially inhibited. In addition to HLA competition, the induction of anergy, but not direct TCR antagonism, was observed. Numerous GA-specific TCC were generated from the peripheral blood of both MS patients and normal controls, and a fraction of these showed a Th2 phenotype.
Conclusions: This study confirms a preferential inhibitory effect of GA on autoreactive TCC. With respect to cellular mechanisms, although HLA competition appears to play the most important role in functional inhibition in vitro, a direct effect on the TCR may be involved at least in some autoreactive T cells as shown by anergy induction. Although not confirmed at the clonal level, it is demonstrated further that GA induces T cells that crossreact with myelin proteins. GA-specific, Th2-modulatory cells may play an important role in mediating the effect of the drug in vivo.
American Academy of Neurology